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The objective of this research was to develop and validate an
analytical method for quantitative determination of ciprofloxacin
(CIP) and norfloxacin (NOR) in pharmaceutical preparations. A
simple and rapid chromatographic method was developed and
validated for quantitative determination of two fluoroquinolone
antibiotics in tablets and injection preparations. The quinolones
were analyzed by using a LiChrospher® 100 RP-18 column
(5 µm, 125 x 4 mm) and a mobile phase consisted of
water:acetonitrile:triethylamine (80:20:0.3 v/v/v). The pH of final
mixture was adjusted to 3.3 with phosphoric acid. The flow rate
was 1.0 mL/min and UV detection was made at 279 nm. The
analyses were performed at room temperature (24 ± 2 ºC). CIP
and NOR were eluted within 5 min. The calibration curves were
linear (r > 0.9999) over a concentration range from 4.0 to 24.0
µg/mL. The relative standard deviation (RSD) was < 1.0% and
the mean recovery was 101.85%.
INTRODUCTION
Fluoroquinolones comprise a series of broad-
spectrum synthetic antibacterial agents derived from
nalidixic acid. They were discovered casually in 1962 and
since then are essentially used in the treatment of several
infectious diseases (Bertino and Fish, 2000; Fierens,
Hillaert and Van Den Bossche, 2000; Marzo and Dal Bo,
2002; Arteseros et al., 2002).
Ciprofloxacin (CIP) and norfloxacin (NOR) are
quinolones with fluorine at position 6 of naphthyridine ring.
The chemical structures of fluoroquinolones are shown in
Figure 1. Published structure-activity data shows that
fluorine atom help broadens their activity spectrum against
both gram-negative and gram-positive pathogens (Lorian,
1996; Bertino, Fish, 2000; Fierens, Hillaert and Van Den
Bossche, 2000; Arteseros et al., 2002; Samanidou,
Demetriou, Papadoyannis, 2003).
The primary target of fluoroquinolones is bacterial
enzyme DNA gyrase or topoisomerase II (Mandel, Petri
Júnior, 1996; Bertino, Fish, 2000; Marzo, Dal Bo, 2000;
Arteseros et al., 2002). They are generally well tolerated, safe
and adverse effects vary significantly depending on their
physicochemical properties (Mandel, Petri Júnior, 1996;
Bertino, Fish, 2000). Majority of them are well absorbed
through oral route and have a long half-life, being widely
distributed within body tissues and fluids (Marzo, Dal Bo, 2002;
Samanidou, Demetriou, Papadoyannis, 2003).
Due to the minor structural differences amongst
members of the same group, it is difficult to identify and to
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determine their respective degradation products (Joshi, 2002).
Several analytical methods for quantitative determination of
fluoroquinolones in pharmaceutical formulations are described
in scientific literature, like capillary electrophoresis (Bhowal,
Das, 1991; Flurer, 1997; Sun, Chen, 1997), UV spectro-
photometry (Fratini, Schapoval, 1996; Chowdary, Rao, 1997),
titrimetry (Belal, Al-Majed, Al-Obaid, 1999), and high
performance liquid chromatography (HPLC) (United States
Pharmacopeia , 2004; British Pharmacopoeia, 1999; Mazuel,
1991), amongst others.
HPLC is widely employed for the determination of
CIP and NOR either in biological fluids, edible animal
products, feed and pharmaceutical formulations (Barbosa,
Berges, Sanz-Nebot, 1996; Belal, Al-Majed, Al-Obaid,
1999; Budvari-Barany et al. 1991; Córdoba-Borrego,
Cordoba-Diaz, Cordoba-Diaz, 1999; Husain et al. 1995;
Kirkland, Mccombs, Kirkland, 1994; Lacroix, Curran,
Sears, 1996; Morley, Erold, 1993; Samanidou,
Christodoulou, Papadoyannis, 2005; Sowinski, Kays, 2004;
Thoppil, Amin, 2000; Tiefenbacher et al. 1994; Torniainen,
Tammilehto, Ulvi, 1996; Vybiralova et al. 2005).
Majority of these HPLC methods were applied in
determination of fluoroquinolones in biological fluids, edible
animal products, feeds and to a lesser extent in
pharmaceutical formulations. Most of the reported
methods involve troublesome mobile phase (buffers) and
difficult sample preparation. The objective of this research
was to develop and validate an efficient HPLC method for
quantitative determination of second-generation
quinolones in pharmaceutical preparations. A rapid,
accurate and sensitivity method was developed for
quantitative determination of two fluoroquinolones: CIP




All solvents were of HPLC grade and reagents were
analytical grade. Acetonitrile and phosphoric acid were
obtained from Merck®. Analytical grade triethylamine was
purchased from Sigma®. Water was purified with Milli-Q®
Plus, Millipore System. All solvents and solutions were
filtered through membrane filter (Millipore Millex® - HV
filter units, Durapore - PVDF, polyethylene, 0.45 µm pore
size) and degassed before use.
The active pharmaceutical ingredients (API)
including CIP (99.5%) and NOR (100.1%) were kindly
donated by a local pharmaceutical industries and were used
as reference standards without further purification.
Samples
The samples used in this research are presented in
Table 1.
TABLE I - Commercial pharmaceutical dosage form
samples of ciprofloxacin and norfloxacin used in the research
Sample Pharmaceutical Drug Pharmaceutical
number industries (a) dosage form
1 A Ciprofloxacin Tablets
    hydrochloride (250 mg)
2 B Ciprofloxacin Tablets
    hydrochloride (500 mg)
3 C Ciprofloxacin Injection 100 mL
    (freebase) (20 mg/mL)
4 D Norfloxacin Tablets
    (freebase) (400 mg)
5 E Norfloxacin Tablets
    (freebase) (400 mg)
(a) Pharmaceutical industries are identified by letters and
samples by numbers
FIGURE 1. Chemical structures of ciprofloxacin and
norfloxacin.
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Instrumentation
A. HPLC System
High performance liquid chromatographic system
model Varian® 5000, equipped with injection valve –
Rheodyne® model 7125 with 20 µL fixed loop, variable
ultraviolet detector Varian® model 4000 and integrator
Varian® model 4400.
B. Column
The analytical column was a reversed phase




All analyses were done at ambient temperature
(24 ± 2 ºC) under isocratic conditions. The mobile phase
consisted of a volumetric mixture of water:aceto-
nitrile:triethylamine (80:20:0.3 v/v/v). The pH of final mixture
was adjusted to 3.3 with phosphoric acid. The flow rate was
1.0 mL/min and volume of injection was 20 µL. All solutions,
including mobile phase, were sonicated during 25 min before
use. The UV detection was made at 279 nm.
Standard solutions preparation
Accurately weighed amount of standards of CIP and
NOR, equivalent to 20.0 mg of freebase were transferred to
100 mL volumetric flasks, separately. The volume was
completed with mobile phase and methanol, in case of CIP
and NOR, respectively. The resulting solutions were sonicated
during 25 min and filtered through a filtration membrane. Fi-
nal concentrations were 200.0 µg/mL. Aliquots of each solution
were accordingly diluted with mobile phase in order to obtain
solutions with final concentration of 50.0 µg/mL.
Calibration curves
Six different concentration levels (4.0, 8.0, 12.0, 16.0,
20.0 and 24.0 µg/mL) were obtained of each standard solution,
conveniently diluted with mobile phase. Each solution was
injected in the chromatographic system (n = 3) and mean
values of peak areas were plotted against concentrations. The
curves were adjusted by linear regression with least mean
square method (Harris, 2001; Leite, 2002).
Linearity
The linearity of the proposed method was evaluated
by using calibration curves to calculate coefficient of
correlation and intercept values.
Sample preparation
Tablets
Twenty tablets of each sample were individually
weighed and triturated to obtain homogeneous mixture. An
amount of powder equivalent to 100.0 mg of freebase, was
transferred to a 100 mL volumetric flask. The volume was
completed with mobile phase for CIP, while for NOR,
methanol was used. The resulting solutions were sonicated
during 25 min to facilitate proper solubilization. All the
solutions were filtered through Whatman filter paper nº 1
Aliquots of each filtered solution were accordingly diluted,
with mobile phase, in order to obtain solutions with final
concentration of 50.0 µg/mL. Assays were performed after
appropriate dilutions of above solution.
Injectable preparations
For injectable sample, 5.0 mL of the solution was
accurately measured and the procedure adopted for
sample preparation was similar to that described for tablets.
Appropriate dilutions were made with mobile phase to fi-
nal solutions containing 50.0 µg/mL of the drug in freebase.
Assays were performed after appropriate dilutions of
above solution.
Specificity
The specificity of proposed method was evaluated by
comparing the results obtained by analysis of placebo
formulations using the proposed method.
Accuracy
To evaluate the accuracy of the proposed method,
recovery tests were carried out with all samples. Recovery
tests were performed by adding known amounts of
standard solutions to sample followed by analysis using the
proposed method. Aliquots of standard and samples
solutions were transferred to 25 mL volumetric flasks and
final volumes were completed with mobile phase. The
percentage of recovery (R%) was calculated as indicated
by Association of Official Analytical Chemists
International (2002).
Precision
The precision of proposed method was evaluated
through intra-day repeatability of responses after replicate
(n = 10) injection of sample solutions (5.0 µg/mL). The
precision is expressed as RSD amongst responses.
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Robustness
The robustness of the proposed method was
evaluated by intentional minor modifications in the
composition of the mobile phase as well as its pH. The
modified mobile phase was used to analyze drug samples
(Chromatograms not shown).
Detection limit (DL) and quantification limit (QL)





SD = Standard deviation of curve,
α = Slope of curve
RESULTS AND DISCUSSION
In order to validate an efficient method for analysis
of drugs in pharmaceutical formulations, preliminary tests
were performed with the objective to select adequate and
optimum conditions. Parameters such as detection
wavelength, ideal mobile phase and their proportions,
optimum pH and concentration of the standard solutions
were exhaustively studied.
Several binary or ternary eluents were tested using
different proportions of solvents such as acetonitrile,
methanol and water. Some ion-pair reagents were also
studied. A flow rate of 1.0mL/min was selected after
preliminary tests.
The proposed method is simple and do not involve
laborious time-consuming sample preparation. The method
was statistically validated for their accuracy and precision.
The chromatograms of sample containing CIP and NOR
can be observed in Figure 2 (a - b) and 2c, respectively. As
could be seen, excipients did not interfere in the analysis
of CIP and NOR using proposed method.
The calibration curves showed linearity over a
concentration range from 4.0 to 24.0 µg/mL. The
correlation coefficients obtain with linear regression of
curve were better than 0.9999. Linearity data shows
concentration interval of studied fluoroquinolones in which
the intensity of the detector response is proportional to the
concentration of the analyzed substance. The DL and QL
of CIP and NOR were 0.16, 0.50 and 0.28, 0.86 µg/mL,
respectively. Table 2 shows the statistical parameters of
CIP and NOR analyzed by the proposed method.
The standard deviation amongst replicate responses
and relative standard deviation values (RSD) were less than
1.0%, indicating precision of the method. The statistical data
results obtained in the analysis of commercially available
samples are shown in Table 3. The recovery values obtained
were between 97.92 and 103.95%, confirming accuracy of
the proposed method. The percentage of recovery results
are presented in Table 4.
FIGURE 2 - Chromatograms of samples: (a) ciprofloxacin
tablet, (b) ciprofloxacin injectable and (c) norfloxacin (15.0
µg/mL). Conditions: LiChrospher® RP-18 column (5 µm,
125 x 4 mm) in LiChroCART®, mobile phase
H2O:MeCN:TEA (80:20:0,3 v/v), pH adjusted to 3.3 with
phosphoric acid, flow rate 1.0 mL/min, UV detection at 279
nm and ambient temperature (24 ± 2 °C).
TABLE II - Statistical results of linear regression analysis
in the determination of CIP and NOR by proposed method
Statistical parameters CIP NOR
Slope of curve (a) 2683.67 2824.41
Intercept of curve (b) -621.93 -1238.84
Standard error of estimative (Se) 165.64 537.46
Standard error of slope (Sb) 9.89 32.12
Standard error of intercept (Sa) 154.20 500.35
Linear correlation coefficient (r) 0.9999 0.9999
Injection levels (n) 3 3
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There was minor delay in the retention time when
pH of the mobile phase varies in 0.5 units. Practically no
effect was observed when mobile phase components
were intentionally deviated. Changes as much as 5 mL of
each component in the mobile phase were altered.
Consequently, due to this observation, the robustness of
the method can be confirmed.
CONCLUSION
The proposed HPLC method enables quantitative
determination of second generation quinolones such as CIP
and NOR in pharmaceutical formulations. UV detection at
279 nm was found to be suitable without any interference
from tablets or injectable solution excipients or solvents. The
calibration curves were found to be linear with correlation
coefficients above 0.9999. The relative standard deviations
values were less than 1.0%. Analytical results of samples
were in accordance with those of standard solution in the
same concentrations. Preparation of samples is easy and
efficient. The proposed HPLC method is fast, precise,
accurate, sensitive, and efficient and can be used in routine
analysis in quality control laboratories.
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RESUMO
Determinação quantitativa do ciprofloxacino e do
norfloxacino em preparações farmacêuticas por
cromatografia líquida de alta eficiência
O objetivo desta pesquisa foi desenvolver e validar um
método analítico para a determinação quantitativa do
ciprofloxacino (CIP) e do norfloxacino (NOR) em prepa-
rações farmacêuticas. Um método cromatográfico sim-
ples e rápido foi desenvolvido e validado para a deter-
minação quantitativa de dois antibióticos fluoroquino-
lônicos em comprimidos e injetáveis. As quinolonas fo-
ram analisadas empregando-se uma coluna RP-18,
LiChrospher® 100 (125 x 4 mm, 5µm) e fase móvel cons-
tituída por água:acetonitrila:trietilamina (80:20:0.3 v/v/
v). O pH da mistura final foi ajustado a 3,3 com ácido
fosfórico. A vazão da fase móvel foi de 1,0 mL/min e a
detecção em UV a 279 nm. As análises foram realizadas
à temperatura ambiente (24±2 ºC). O CIP e o NOR
eluíram em menos de 5 min. As curvas de calibração
foram lineares (r > 0.9999) na faixa de concentração
entre 4,0 e 24,0 µg/mL. O desvio padrão relativo (RSD)
foi < 1,0% e a recuperação média foi de 101,85%.
UNITERMOS: Ciprofloxacino. Norfloxacino. Prepa-
rações farmacêuticas. CLAE.
TABLE IV - Recovery data of standard solutions added to
the samples analyzed by using the proposed HPLC method
Sample Amount Amount Recovery Mean
number added found Recovery
(Drug) (µg/mL) (µg/mL) (%) (%)
1(CIP) 12.0 12.34 103.29
14.0 14.20 100.77 102.22
16.0 16.40 102.60
2(CIP) 12.0 11.95 101.49
14.0 14.06 102.44 101.40
16.0 15.89 100.27
3(CIP) 12.0 12.23 102.69
14.0 14.14 100.91 100.51
16.0 15.86 97.92
4(NOR) 12.0 12.19 102.57
14.0 14.09 100.67 102.40
16.0 16.43 103.95
5(NOR) 12.0 12.06 102.72
14.0 14.10 102.56 102.72
16.0 16.18 102.87
(a) Average of three determinations
TABLE III - Statistical data obtained in the analysis of samples using the proposed method
Sample number Declared theoretical Found experimental SD* RSD(%) Content (%)
(Drug) concentration (µg/mL) concentration(µg/mL)* Confidence interval**
1(CIP) 15.00 15.51 0.08 0.51 103.38 ± 0.06
2(CIP) 15.00 16.05 0.13 0.78 107.01 ± 0.09
3(CIP) 15.00 15.06 0.08 0.51 100.43 ± 0.06
4(NOR) 15.00 14.94 0.06 0.40 099.59 ± 0.04
5(NOR) 15.00 14.91 0.11 0.74 099.41 ± 0.08
(*) Average of ten determinations(**) 95.0% confidence level
N. M. Kassab, A. K. Singh, E. R. M. Kedor-Hackmam, M. I. R. M. Santoro512
REFERENCES
ARTESEROS, J.A.H.; BARBOSA, J.; COMPANO, R.;
PRAT, M.D. Analysis of quinolone residues in edible
animal products. J. Chromatogr. A, Amsterdam, v.945,
p.1-24, 2002.
ASSOCIATION OF OFFICIAL ANALYTICAL
CHEMISTS INTERNATIONAL. Official methods of
analysis of AOAC International. 17 ed. Gaithersburg:
AOAC, 2002. v.1, p.xx.
BARBOSA, J.; BERGES, R; SANZ-NEBOT, V.
Solvatochromic parameter values and pH in aqueous-
organic mixture and use in liquid chromatography.
Prediction of retention of series of quinolones. J.
Chromatogr., A, Amsterdam, v.719, p.27-36, 1996.
BELAL, F.; AL-MAJED, A.A.; AL-OBAID, A.M. Methods
of analysis of 4-quinolone antibacterials. Talanta,
Amsterdam, v.50, n.4. p.765-786, 1999.
BERTINO, J.; FISH, D. Safety profiles of the fluoroquinolones.
Clin. Ther., Hillsborough, v.22, p.798-817, 2000.
BHOWAL, S.K.; DAS, T.K. Spectrophotometric
determination of same recently introduced antibacterial
drugs using ferric chloride. Anal. Lett., New York, v.24,
p.25-37, 1991.
BRITISH pharmacopoeia 1999. London: Her Majesty’s
Stationery Office, 1999. p.369-370, 1034-1035.
BUDVARI-BARANY, Z.S.; SZASZ, G.Y.; TAKACS-
NOVAK, K.; HERMECZ, I.; LORE, A. The pH
influence on the HPLC-retention of chemotherapeutic
fluorquinolone derivatives. J. Liq. Chromatogr., New
York, v.14, p.3411-3424, 1991.
CHOWDARY, K.P.R.; RAO, G.D. Spectrophotometric
method for the determination of lomefloxacino
hydrochroride. Indian Drugs, Mumbai, v.34, p.107-108,
1997.
CORDOBA-BORREGO, M.; CORDOBA-DIAZ, M.;
CORDOBA-DIAZ, D. Validation of high-performance
liquid chromatographic method for the determination of
norfloxacin and its application to stability studies (photo-
stability study of norfloxacin). J. Pharm. Biomed. Anal.,
Amsterdam, v.18, p.919-926, 1999.
FIERENS C.; HILLAERT. S.; VAN DEN BOSSCHE W.
The qualitative and quantitative determination of
quinolones of first and second generation by capillary
electrophoresis. J. Pharm. Biomed. Anal., Amsterdam,
v.22, p.763-772, 2000.
FLURER, C.L. Analysis of antibiotics by capillary
electrophoresis. Electrophoresis, Weinheim, v.18,
p.2427-2437, 1997.
FRATINI, L.; SCHAPOVAL, E.E.S. Ciprofloxacin
determination by visible light spectrophotometry using
iron(III) nitrate. Int. J. Pharm., Amsterdam, v.127, p.279-
282, 1996.
HARRIS, D.C. Métodos de calibração. In: _____. Análise
química quantitativa. 5.ed. Rio de Janeiro: Livros
Técnicos e Científicos, 2001. p.81-95.
HUSAIN, S.; KHALID, S.; NAGARAJU, V.; RAO, R.N.
High-performance liquid chromatographic separation and
determination of small amounts of process impurities of
ciprofloxacin in bulk drugs formulations. J. Chromatogr.,
A, Amsterdam, v.705, p.380-384, 1995.
JOSHI, S. HPLC separation of antibiotics present in
formulated and unformulated samples. J. Pharm.
Biomed. Anal., Amsterdam, v.28, p.795-809, 2002.
KIRKLAND, K.M.; MCCOMBS, D.A.; KIRKLAND, J.J.
Rapid, high-resolution high-performance liquid
chromatography of antibiotics. J. Chromatogr., A,
Amsterdam, v.660, p.327-337, 1994.
LACROIX, P.M.; CURRAN, N.M.; SEARS, R.W. High-
pressure liquid chromatographic methods for ciprofloxacin
hydrochloride and related compounds in raw materials. J.
Pharm. Biomed. Anal., Amsterdam, v.14, p.641-654,
1996.
LEITE, F. Validação em análise química. 4.ed. São Paulo:
Átomo, 2002. p.69-72.
LORIAN, V. Antibiotics in Laboratory Medicine. 4.ed.
Baltimore: Williams & Wilkins, 1996. p. 591-592.
MANDEL, G.I.; PETRI JUNIOR, W.A. Antimicrobial
agents: sulfonamides, trimethoprim-sulfamethoxazole,
quinolones, and agents for tract infections. In: Goodman
& Gilman’s: The pharmacological basis of therapeutics.
9. ed. New York: Mcgraw-Hill, 1996. p. 1065-1068.
Quantitative determination of ciprofloxacin and norfloxacin 513
MARZO, A.; DAL BO, L. Chromatography as an analytical
tool for selected antibiotic classes: a reappraisal addressed
to pharmacokinetic applications. J. Chromatogr. A,
Amsterdam, v.812, p.17-34, 2002.
MAZUEL, C. Norfloxacin. Anal. Profiles Drug Subst.
Excipients, San Diego, v.20, p.557-600, 1991.
MORLEY, J.A.; EROLD Jr., L. Determination of
fluorquinolne antibacterial as N-Acyl derivatives.
Chromatographia, Wiesbaden, v.37, p.295-299, 1993.
SAMANIDOU, V.F.; CHRISTODOULOU, E.A.;
PAPADOYANNIS, I.N. Determination of
fluoroquinolones in edible animal tissue samples by high
performance liquid chromatography after solid phase
extraction. J. Sep. Sci., Weinheim, v. 28, p. 555-565,
2005.
SAMANIDOU, V.F.; DEMETRIOU, C.E.;
PAPADOYANNIS, I.N. Direct determination of four
fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and
ciprofloxacin, in pharmaceuticals and blood serum by
HPLC. Anal. Bioanal. Chem., Heidelberg, v.375, p.623-
629, 2003.
SOWINSKI, K.M.; KAYS, M.B. Determination of
ciprofloxacin concentrations in human serum and urine by
HPLC with ultraviolet and fluorescence detection. J. Clin.
Pharm. Ther., Oxon, v. 29, p. 381-387, 2004.
SUN, S.-W.; CHEN, L.-Y. Optimization of capillary
electrophoretic separation of quinolones antibacterials
using the overlapping resolution mapping scheme. J.
Chromatogr., A, Amsterdam, v.766, p.215-224, 1997.
THOPPIL, S.O.; AMIN, P.D. Stability indicating reversed-
phase liquid chromatographic determination of
ciprofloxacin as bulk drug and in pharmacetical
formulations. J. Pharm. Biomed. Anal., Amsterdam,
v.22, p.699-703, 2000.
TIEFENBACHER, E.M.; HAEN, E.; PRZYBILLA, B.;
KURZ, H. Photodegradation of some quinolones used as
antimicrobial therapeutics. J. Pharm. Biomed. Anal.,
Amsterdam, v.83, p.463-467, 1994.
TORNIAINEN, K.; TAMMILEHTO, S.; ULVI, V. The
effect of pH, buffer type and drug concentration on the
photodegradation of ciprofloxacin. Int. J. Pharm.,
Amsterdam, v.132, p.53-61, 1996.
UNITED States Pharmacopeia. 27.ed. Rockville: United
States Pharmacopeial Convention, 2004. p.454-457, 1342-
1343.
VYBIRALOVA, Z.; NOBILIS, M.; ZOULOVA, J.;
KVETINA, J.; PETR, P. High-performance liquid
chromatographic determination of ciprofloxacin in plasma
samples. J. Pharm. Biomed. Anal., Oxford, v. 37, p. 851-
858, 2005.
Recebido para publicação em 17 de dezembro de 2004.
Aceito para publicação em 18 de agosto de 2005.
